Previous close | 2.0900 |
Open | 2.0900 |
Bid | 2.0200 x 1400 |
Ask | 2.2000 x 1800 |
Day's range | 2.0101 - 2.1999 |
52-week range | 1.8100 - 3.3300 |
Volume | |
Avg. volume | 17,847 |
Market cap | 10.131M |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.
After losing some value lately, a hammer chart pattern has been formed for Can-Fite Biopharma Ltd (CANF), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
VRT, PGR and CANF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 27, 2023.